Document:

Exhibit 4.8

Exhibit 4.8

THIS WARRANT AND THE SHARES PURCHASABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE
SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR QUALIFICATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE
SECURITIES LAWS.

THIS WARRANT AND THE SHARES PURCHASABLE HEREUNDER ARE SUBJECT TO RESTRICTIONS ON TRANSFER CONTAINED
IN THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT, DATED AS OF MARCH 26, 2010, AS AMENDED BY THAT
OMNIBUS AMENDMENT DATED AS OF NOVEMBER 15, 2010, WHICH RESTRICTIONS ON TRANSFER ARE INCORPORATED
HEREIN BY REFERENCE.

Dated: November 15, 2010

WARRANT TO PURCHASE

COMMON STOCK OF

VIA PHARMACEUTICALS, INC.

This certifies that Bay City Capital Fund IV Co-Investment Fund, L.P. or its assigns
(collectively, the “Holder”), for value received, is entitled to purchase, at a price of $0.071 per
share (the “Exercise Price”), from VIA Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), up to 891,549 of fully paid and nonassessable shares of the Company’s Common Stock (the
“Warrant Shares”), par value $0.001 per share (the “Common Stock”).

Reference is hereby made to that certain Note and Warrant Purchase Agreement dated as of March
26, 2010, as amended by that Omnibus Amendment dated as of November 15, 2010 (as so amended and as
may be amended or restated from time to time, the “Agreement”) by and between the Company and the
investors set forth on Schedule A thereto, pursuant to which the Company shall issue to Holder this
Warrant and an Amended and Restated Promissory Note in the form attached as Exhibit A to the
Agreement (the “Note”).

The Warrant is vested and exercisable with respect to 59,845 Warrant Shares as of the date
hereof.

At each Drawdown (as defined in the Note), the Warrant shall vest and become exercisable (on a
cumulative basis) with respect to an additional number of Warrant Shares equal to the quotient of
(x) the principal amount of such Drawdown, divided by (y) the Exercise Price (with such quotient
being rounded down to the nearest whole number).

The Warrant Shares subject to this Warrant are set forth on Schedule I hereto, as
shall be appropriately and promptly updated by the Company upon the occurrence of each Drawdown.

 

 

 

To the extent this Warrant is vested and exercisable with respect to any Warrant Shares
pursuant to the preceding paragraph, this Warrant shall be exercisable with respect to such Warrant
Shares at any time from time to time up to and including 5:00 p.m. (Pacific Time) on the five year
anniversary of the date hereof (such earlier time being referred to herein as the “Expiration
Date”), upon surrender to the Company at its principal office (or at such other location as the
Company may advise the Holder in writing) of this Warrant properly endorsed with (i) the Form of
Subscription attached hereto duly completed and executed and (ii) payment pursuant to Section 2 of
the aggregate Exercise Price for the number of shares for which this Warrant is being exercised
determined in accordance with the provisions hereof. The Exercise Price and the number of shares
purchasable hereunder are subject to adjustment as provided in Section 4 of this Warrant.

1. Exercise; Issuance of Certificates; Acknowledgement. To the extent that this
Warrant is vested and exercisable with respect to any Warrant Shares, this Warrant shall be
exercisable at the option of the holder of record hereof, at any time or from time to time up to
the Expiration Date for all or any part of such Warrant Shares (but not for a fraction of a share)
for which this Warrant is vested and exercisable at such time. The Company agrees that the shares
of Common Stock purchased under this Warrant shall be and are deemed to be issued to the Holder
hereof as the record owner of such shares as of the close of business on the date on which this
Warrant shall have been surrendered, properly endorsed, the completed, executed Form of
Subscription delivered and payment made for such shares. Certificates for the shares of the Common
Stock so purchased, together with any other securities or property to which the Holder hereof is
entitled upon such exercise, shall be delivered to the Holder hereof by the Company at the
Company’s expense within three business days after the rights represented by this Warrant have been
so exercised, and may bear a restrictive legend in substantially the form set forth in Section 3.6
of the Agreement. Each certificate so delivered shall be in such denominations of the Warrant
Shares as may be requested by the Holder hereof and shall be registered in the name of such Holder.
In case of a purchase of less than all the Warrant Shares, the Company shall execute and deliver
to Holder within seven business days an Acknowledgement in the form attached hereto indicating the
number of Warrant Shares which remain subject to this Warrant, if any, and the number of Warrant
Shares for which this Warrant is vested and exercisable at such time, if any. Notwithstanding
anything to the contrary contained herein, unless the Holder otherwise notifies the Company or the
Exercise Price exceeds the fair market value of a Warrant Share (as determined in Section 2 below),
this Warrant shall be deemed to be automatically exercised using the Net Issuance Method pursuant
to Section 2 hereof immediately prior to the time on the Expiration Date at which this Warrant
ceases to be exercisable. In addition, the Holder may specify in its Form of Subscription
delivered to the Company (along with payment for the shares by cash or wire transfer) that the
Holder’s exercise of any portion of this Warrant is contingent upon the closing of a then-pending
Fundamental Transaction (as defined below). Upon any exercise of this Warrant, the Holder shall,
if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the
Warrant Shares so purchased are being acquired solely for the Holder’s own account and not as a
nominee for any other party, for investment and not with a view toward distribution or resale and
that such Holder is an “accredited investor” as such term is defined in Rule 501(a)(1) of
Regulation D promulgated by the Securities and Exchange Commission under the Securities Act of
1933, as amended. If the Holder cannot make such representations because they would be factually
incorrect, it shall be a condition to such Holder’s exercise of this Warrant that the Company
receive such other
representations as the Company considers reasonably necessary to assure the Company that the
issuance of its securities upon exercise of this Warrant shall not violate any United States or
state securities laws.

 

2

 

2. Payment for Shares. The aggregate purchase price for Warrant Shares being
purchased hereunder may be paid either (i) by cash or wire transfer of immediately available funds,
(ii) if the fair market value of one (1) share of the Warrant Shares on the date of exercise is
greater than the Exercise Price, by surrender of a number of Warrant Shares which have a fair
market value equal to the aggregate purchase price of the Warrant Shares being purchased (“Net
Issuance”) as determined herein, or (iii) any combination of the foregoing. If the Holder elects
the Net Issuance method of payment, the Company shall issue to Holder upon exercise a number of
shares of Warrant Shares determined in accordance with the following formula:

	 	 	 
	X=

	 	Y(A-B)
	 	A

	 	 	 
	where: X =

	 	the number of Warrant Shares to be issued to the Holder;
	 
	 	 
	Y =

	 	the number of Warrant Shares with respect to which the Holder is
exercising its purchase rights under this Warrant;
	 
	 	 
	A =

	 	the fair market value of one (1) share of the Warrant Shares on the
date of exercise; and
	 
	 	 
	B =

	 	the Exercise Price.

No fractional shares arising out of the above formula for determining the number of shares to
be issued to the Holder shall be issued, and the Company shall in lieu thereof make payment to the
Holder of cash in the amount of such fraction multiplied by the fair market value of one (1) share
of the Warrant Shares on the date of exercise. For purposes of the above calculation, the fair
market value of one (1) share of the Warrant Shares shall mean (a) if the Common Stock is then
traded on a securities exchange, the average of the closing prices of such Common Stock on such
exchange over the ten (10) calendar day period ending three (3) days prior to the date of exercise,
(b) if the Common Stock is then regularly traded over-the-counter, the average of the closing sale
prices or secondarily the closing bid of such Common Stock over the ten (10) calendar day period
ending three (3) days prior to the date of exercise, or (c) if there is no active public market for
the Common Stock, the fair market value of one share of the Warrant Shares as determined in good
faith by the Board of Directors of the Company.

3. Reservation of Shares; Shares to be Fully Paid. The Company covenants and agrees
that all shares of Common Stock which may be issued upon the exercise of the rights represented by
this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable
and free from all preemptive rights of any stockholder and free of all taxes, liens and charges
with respect to the issue thereof. The Company represents and warrants that it has reserved a
sufficient number of authorized but unissued shares of Common Stock to provide for the exercise of
the rights represented by this Warrant (assuming full vesting thereof).

 

3

 

4. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the
number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from
time to time upon the occurrence of certain events described in this Section 4. Upon each
adjustment of the Exercise Price, the Holder of this Warrant shall thereafter be entitled to
purchase, at the Exercise Price resulting from such adjustment, the number of shares obtained by
multiplying the Exercise Price in effect immediately prior to such adjustment by the number of
shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product
thereof by the Exercise Price resulting from such adjustment.

4.1 Subdivisions, Combinations and Dividends. In case the Company shall at any time
subdivide its outstanding shares of Common Stock into a greater number of shares or pay a dividend
in Common Stock in respect of outstanding shares of Common Stock, the Exercise Price in effect
immediately prior to such subdivision or at the record date of such dividend shall be
proportionately reduced, and conversely, in case the outstanding shares of the Common Stock of the
Company shall be combined into a smaller number of shares, including by means of a reverse stock
split, the Exercise Price in effect immediately prior to such combination shall be proportionately
increased.

4.2 Reclassification. If any reclassification of the capital stock of the Company
shall be effected in such a way that holders of Common Stock shall be entitled to receive stock,
securities, or other assets or property, then, as a condition of such reclassification, lawful and
adequate provisions shall be made whereby the Holder hereof shall thereafter have the right to
purchase and receive (in lieu of the shares of the Common Stock immediately theretofore purchasable
and receivable upon the exercise of the rights represented hereby) such shares of stock, securities
or other assets or property as may be issued or payable with respect to or in exchange for a number
of outstanding shares of such Common Stock equal to the number of shares of such Common Stock
immediately theretofore purchasable and receivable upon the exercise of the rights represented
hereby. In any reclassification described above, appropriate provision shall be made with respect
to the rights and interests of the Holder of this Warrant to the end that the provisions hereof
(including, without limitation, provisions for adjustments of the Exercise Price and of the number
of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be
applicable, as nearly as may be, in relation to any shares of stock, securities or assets
thereafter deliverable upon the exercise hereof.

4.3 Notice of Adjustment. Upon any adjustment of the Exercise Price or any increase
or decrease in the number of shares purchasable upon the exercise of this Warrant, the Company
shall give written notice thereof, by first class mail postage prepaid, addressed to the registered
Holder of this Warrant at the address of such Holder as shown on the books of the Company. The
notice shall be signed by the Company’s chief financial officer and shall state the Exercise Price
resulting from such adjustment and the increase or decrease, if any, in the number of shares
purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the
method of calculation and the facts upon which such calculation is based.

5. No Voting or Dividend Rights. Nothing contained in this Warrant shall be construed
as conferring upon the Holder hereof the right to vote or to consent to receive notice as a
stockholder of the Company or any other matters or any rights whatsoever as a stockholder of the
Company. No dividends or interest shall be payable or accrued in respect of this Warrant or
the interest represented hereby or the shares purchasable hereunder until, and only to the
extent that, this Warrant shall have been exercised.

 

4

 

6. Fundamental Transaction. If, at any time while this Warrant is outstanding, (A) the
Company effects any merger or consolidation of the Company with or into another entity or person,
(B) the Company effects any sale of all or substantially all of its assets (including but not
limited to an exclusive license of all or substantially all of the intellectual property of the
Company) in one or a series of related transactions, (C) any tender offer or exchange offer
(whether by the Company or another entity) is completed pursuant to which holders of Common Stock
are permitted to tender or exchange their shares for other securities, cash or property, or (D) the
Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property (in any such case, a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that
would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitations on exercise contained herein), upon exercise of this
Warrant, the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and/or any other consideration (the “New
Consideration”), in each case that the Holder would have received upon or as a result of such
Fundamental Transaction if the Holder had exercised this Warrant immediately prior to such event
(without regard to any limitations on exercise contained herein). For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to reflect the
amount of New Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the New Consideration in a
reasonable manner reflecting the relative value of any different components of the New
Consideration. If holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the New Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any
successor to the Company or surviving entity in such Fundamental Transaction shall issue to the
Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to
exercise such warrant into the New Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such successor or surviving
entity to comply with the provisions of this Section 6 and insuring that this Warrant (or any such
replacement security) will be similarly adjusted upon any subsequent transaction analogous to a
Fundamental Transaction.

7. Warrants Transferable. Subject to compliance with applicable federal and state
securities laws and the transfer restrictions set forth in Sections 3.4, 3.5 and
3.6 of the Agreement under which this Warrant was issued, this Warrant and all rights
hereunder may be transferred, in whole or in part, without charge to the holder hereof (except for
transfer taxes), upon surrender of this Warrant properly endorsed and in compliance with the
provisions of the Agreement. Each taker and holder of this Warrant, by taking or holding the same,
consents and agrees that this Warrant, when endorsed in blank, shall be deemed negotiable, and that
the holder hereof, when this Warrant shall have been so endorsed, may be treated by the Company, at
the Company’s option, and all other persons dealing with this Warrant as the absolute owner hereof
for any purpose and as the person entitled to exercise the rights represented by this Warrant,
or to the transfer hereof on the books of the Company and notice to the contrary notwithstanding;
but until such transfer on such books, the Company may treat the registered owner hereof as the
owner for all purposes.

 

5

 

8. Lost Warrants. Upon receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction, or mutilation of this Warrant and, in the case of any such loss,
theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in
the case of any such mutilation upon surrender and cancellation of such Warrant, the Company, at
its expense, will make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen,
destroyed or mutilated Warrant.

9. Modification and Waiver. Any term of this Warrant may be amended and the
observance of any term of this Warrant may be waived (either generally or in a particular instance
and either retroactively or prospectively), only with the written consent of the Company and the
Holder.

10. Notices. Except as may be otherwise provided herein, all notices, requests,
waivers and other communications made pursuant to this Warrant shall be made in accordance with
Section 5.6 of the Agreement.

11. Governing Law; Jury Trial Waiver. This Warrant is to be construed in accordance
with and governed by the laws of the State of Delaware. THE HOLDER AND THE COMPANY HEREBY
KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS
WARRANT. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE HOLDER’S ACQUISITION OF THIS WARRANT.

 

6

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its officers,
thereunto duly authorized as of the date first above written.

	 	 	 	 	 
	 	VIA PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/
Karen S. Wright	 
	 	 	Name:  	Karen S. Wright	 
	 	 	Title:  	Vice
President, Controller	 

[Signature page to Warrant for Bay City Capital Fund IV Co-Investment Fund, L.P.]

 

7

 

SCHEDULE I

Warrant Shares subject to Warrant issued to Bay City Capital Fund IV Co-Investment Fund, L.P.

November 15, 2010 Drawdown

Warrant Shares Immediately Exercisable: 59,845

 

 

 

FORM OF SUBSCRIPTION

(To be signed only upon exercise of Warrant)

To: VIA Pharmaceuticals, Inc.

The undersigned, the holder of a right to purchase shares of Common Stock of VIA
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to that certain Warrant to
Purchase Common Stock of VIA Pharmaceuticals, Inc. (the “Warrant”), dated as of November 15, 2010,
hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to
purchase thereunder,                                          (                    ) shares of Common Stock of the Company
and herewith makes payment of                                          Dollars ($                    ) therefor by
the following method:

(Check one of the following):

	 	 	 
	o (check if applicable)

	 	The undersigned hereby elects to make payment of
                     Dollars ($                    ) therefor in cash.
	 
	 	 
	o (check if applicable)

	 	The undersigned hereby elects to make payment for the aggregate
exercise price of this exercise using the Net Issuance method pursuant to Section 2 of the
Warrant.

The undersigned represents that it is acquiring such securities for its own account for
investment and not with a view to or for sale in connection with any distribution thereof and in
order to induce the issuance of such securities makes to the Company, as of the date hereof, the
representations and warranties set forth in Section 3 of the Note and Warrant Purchase
Agreement, dated as of March 26, 2010, as amended by that Omnibus Amendment dated as of November 15, 2010, by and among the Company and the investors set forth on Schedule A thereto.

DATED:                     

	 	 	 	 	 	 	 	 	 
	 	 	[                    ]	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Name:	 	 	 	 
	 

	 	 	 	Its:
	 	 

	 	 
	 

	 	 	 	 	 	 

	 	 

 

 

 

ACKNOWLEDGMENT

To:                     

The undersigned hereby acknowledges that as of the date hereof,                     
(                    ) shares of Common Stock remain subject to the right of purchase in favor of
                    . pursuant to that certain Warrant to Purchase Common Stock of VIA
Pharmaceuticals, Inc., dated as of November 15, 2010.

DATED:                     

	 	 	 	 	 	 	 	 	 
	 	 	VIA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Name:	 	 	 	 
	 

	 	 	 	Title:Exhibit 4.11

Exhibit 4.11

SECOND AMENDMENT TO THE SECOND AMENDED AND RESTATED 

REGISTRATION RIGHTS AGREEMENT

THIS SECOND AMENDMENT TO THE SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this
“Second Amendment”), dated as of November 15, 2010, is made and entered into by and among
VIA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each of the parties
listed on Exhibit A hereto, as such Exhibit A may be amended from time to time
(collectively, the “Stockholders”). For the purposes of this Agreement, the term “Company”
shall be deemed to include and refer to any successor in interest to the Company, whether by means
of statutory conversion, merger, consolidation, recapitalization, reorganization or otherwise.

RECITALS

WHEREAS, certain of the Stockholders are parties to the Second Amended and Restated
Registration Rights Agreement, dated as of March 12, 2009, as amended by the First Amendment to the
Second Amended and Restated Registration Rights Agreement dated as of March 26, 2010 (as so
amended, the “Registration Rights Agreement”), pursuant to which the Company has granted
certain registration rights under the Securities Act with respect to shares of Common Stock held by
such Stockholders;

WHEREAS, the Company and certain Stockholders party hereto are entering into an amendment (the
“Amendment”) to that certain Note and Warrant Purchase Agreement dated as of March 26, 2010
(the “Purchase Agreement”) and are amending and restated those certain Promissory Notes of
the Company, each dated March 26, 2010 (the “Promissory Notes”), and as an inducement and
partial consideration for such Stockholders entering into the Amendment and amending and restating
the Promissory Notes, the Company is issuing to such Stockholders Warrants to Purchase Common Stock
of VIA Pharmaceuticals, Inc. (collectively, the “Additional 2010 Warrants”), dated
as of the date hereof, pursuant to which the Company is granting to such Stockholders the right to
purchase from the Company an aggregate of 42,253,521 shares of Common Stock on the terms and
conditions set forth in the Additional 2010 Warrants;

WHEREAS, in accordance with the terms of the Purchase Agreement, as amended by the Amendment
(as so amended, the “Amended Purchase Agreement”) and the Additional 2010 Warrants, the
Company desires to amend the Registration Rights Agreement to provide certain registration rights
to the Stockholders party to the Additional 2010 Warrants with respect to the shares of Common
Stock underlying the Additional 2010 Warrants;

WHEREAS, the provisions of the Registration Rights Agreement may be amended or waived at any
time by written agreement of the Company and the Stockholders of at least a majority of the
Registrable Common Stock (as defined in the Registration Rights Agreement); and

WHEREAS, the Company and the Stockholders of at least a majority of the Registrable Common
Stock (as defined in the Registration Rights Agreement) desire to amend the Registration Rights
Agreement to provide for such registration rights to the Stockholders with respect to the shares of
Common Stock underlying the Additional 2010 Warrants.

 

 

 

NOW, THEREFORE, in consideration of the recitals and the mutual premises, covenants and
agreements herein contained and other good and valid consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties to this Second Amendment hereby agree as follows:

1. Amendment. The Registration Rights Agreement shall be amended as follows:

(a) The following definition shall be added to Section 1 of the Registration Rights Agreement:

‘“Additional 2010 Warrants” shall mean the warrants to purchase (in
the aggregate) 42,253,521 shares of Common Stock of the Company issued
pursuant to each Warrant to Purchase Common Stock of VIA Pharmaceuticals,
Inc., as dated November 15, 2010.’

(b) The definition of “Warrants” shall be deleted and replaced with the following:

‘“Warrants” shall mean the 2009 Warrants, the 2010 Warrants, and the
Additional 2010 Warrants.’

2. Effective Time and Remainder of Agreement. This Second Amendment shall be effective as of
the date hereof and, except as set forth herein, the Registration Rights Agreement shall remain in
full force and effect and shall be otherwise unaffected hereby.

3. Miscellaneous.

(a) This Second Amendment and the rights and duties of the parties shall be governed by the
laws of the State of Delaware (without regard to conflicts of laws principles).

(b) This Second Amendment may be executed in any number of counterparts (including by
facsimile) and by different parties hereto in separate counterparts, with the same effect as if all
parties had signed the same document. All such counterparts shall be deemed an original, shall be
construed together and shall constitute one and the same instrument. This Second Amendment shall
become effective when each party hereto shall have received counterparts hereof signed by all of
the other parties hereto.

(c) The headings and other captions in this Second Amendment are for convenience and reference
only and shall not be used in interpreting, construing or enforcing any provision of this Second
Amendment.

(d) If any term, provision, covenant or restriction of this Second Amendment is held by a
court of competent jurisdiction or other authority to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this Second Amendment shall
remain in full force and effect and shall in no way be affected, impaired or invalidated so long as
the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such a determination, the parties shall negotiate in
good faith to modify this Second Amendment so as to affect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby
be consummated as originally contemplated to the fullest extent possible.

[Signature Pages Follow]

 

 

 

IN WITNESS WHEREOF, this Second Amendment to the Second Amended and Restated Registration
Rights Agreement has been duly executed by each of the parties hereto as of the date first written
above.

	 	 	 	 	 	 	 
	VIA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Lawrence K. Cohen	 	 
	 	 	 	 	 
	 

	 	Name:	 	Lawrence K. Cohen	 	 
	 

	 	Title:
	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	BAY CITY CAPITAL FUND IV, L.P.	 	 
	 
	 	 	 	 	 	 
	By: Bay City Capital Management IV LLC	 	 
	Its: General Partner	 	 
	 
	 	 	 	 	 	 
	By: Bay City Capital LLC, its manager	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Fred Craves	 	 	 	 
	 	 	 	 	 
	 

	 	Name:	 	Fred
Craves	 	 
	 

	 	Title:
	 	Managing Director	 	 
	 
	 	 	 	 	 	 
	BAY CITY CAPITAL FUND IV	 	 
	CO-INVESTMENT FUND, L.P.	 	 
	 
	 	 	 	 	 	 
	By: Bay City Capital Management IV LLC	 	 
	Its: General Partner	 	 
	 
	 	 	 	 	 	 
	By: Bay City Capital LLC, its manager	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Fred Craves	 	 	 	 
	 	 	 	 	 
	 

	 	Name:	 	Fred
Craves	 	 
	 

	 	Title:
	 	Managing Director	 	 

[Signature Page to Second Amendment to the Second Amended and Restated Registration Rights Agreement]

 

 

 

Exhibit A

STOCKHOLDERS

	 	 	 	 	 
	Name/Address:	 	 	 
	 
	 	 	 	 
	Bay City Capital Fund IV, L.P.
	 	 	 	 
	Bay City Capital Fund IV Co-Investment Fund, L.P.
	 	 	 	 
	750 Battery Street
	 	 	 	 
	Suite 400
	 	 	 	 
	San Francisco, CA 94111
	 	 	 	 
	 
	 	 	 	 
	Thomas Quertermous
	 	 	 	 
	810 Lathrop Drive
	 	 	 	 
	Stanford, CA 94305
	 	 	 	 
	 
	 	 	 	 
	Adeoye Olukotun
	 	 	 	 
	125 Hopewell-Wertsville Road
	 	 	 	 
	Hopewell, NJ 08525
	 	 	 	 
	 
	 	 	 	 
	Douglass and Kim Given Revocable Trust
	 	 	 	 
	133 Burns Avenue
	 	 	 	 
	Atherton, CA 94027
	 	 	 	 
	 
	 	 	 	 
	Lawrence Cohen
	 	 	 	 
	10065 Broadway Terrace
	 	 	 	 
	Oakland, CA 94611
	 	 	 	 
	 
	 	 	 	 
	Raymond Tabibiazar
	 	 	 	 
	2150 Sterling Avenue
	 	 	 	 
	Menlo Park, CA 94025

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]